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Abstract
AIM: To investigate whether expression of selected 
miRNAs obtained from fibrotic liver biopsies correlate 
with fibrosis stage.
METHODS: Altogether, 52 patients were enrolled in 
the study representing various etiologic backgrounds of 
fibrosis: 24 cases with chronic hepatitis infections (types 
B, C), 19 with autoimmune liver diseases (autoimmune 
hepatitis, primary biliary cirrhosis, primary sclerosing 
cholangitis, overlapping syndrome cases), and 9 of mixed 
etiology (alcoholic and nonalcoholic steatosis, cryptogenic 
cases). Severity of fibrosis was determined by both 
histologic staging using the METAVIR scoring system 
and noninvasive transient elastography. Following RNA 
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isolation, expression levels of miR-21, miR-122, miR-214, 
miR-221, miR-222, and miR-224 were determined 
using TaqMan MicroRNA Assays applying miR-140 
as the reference. Selection of miRNAs was based on 
their characteristic up- or downregulation observed in 
hepatocellular carcinoma. Relative expression of miRNAs 
was correlated with fibrosis stage and liver stiffness (LS) 
value measured by transient elastography, as well as with 
serum alanine aminotransferase (ALT) level.
RESULTS: The expression of individual miRNAs showed 
deregulated patterns in stages F1-F4 as compared 
with stage F0, but only the reduced level of miR-122 in 
stage F4 was statistically significant (P  < 0.04). When 
analyzing miRNA expression in relation to fibrosis, levels 
of miR-122 and miR-221 showed negative correlations 
with fibrosis stage, and miR-122 was found to correlate 
negatively and miR-224 positively with LS values (all P  
< 0.05). ALT levels displayed a positive correlation with 
miR-21 (P  < 0.04). Negative correlations were observed 
in the fibrosis samples of mixed etiology between 
miR-122 and fibrosis stage and LS values (P  < 0.05), 
and in the samples of chronic viral hepatitis, between 
miR-221 and fibrosis stage (P  < 0.01), whereas miR-21 
showed positive correlation with ALT values in the 
samples of autoimmune liver diseases (P  < 0.03). The 
results also revealed a strong correlation between 
fibrosis stage and LS values (P  < 0.01) when etiology 
of fibrosis was not taken into account.
CONCLUSION: Reduced expression of miR-122 in 
advanced fibrosis and its correlation with fibrosis stage 
and LS values seem to be characteristic of hepatic 
fibrosis of various etiologies.
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Core tip: In this study, the expression of selected 
miRNAs was determined in fibrotic liver tissues of 
various etiologic backgrounds and was correlated with 
fibrosis stage (METAVIR scores) and liver stiffness 
as measured by transient elastography. In advanced 
fibrosis, the level of miR-122 was reduced and showed 
negative correlations with fibrosis stage and liver 
stiffness values, indicating that it could be a useful 
molecule to assess severity of fibrosis regardless of 
etiology.
Halász T, Horváth G, Pár G, Werling K, Kiss A, Schaff Z, 
Lendvai G. miR-122 negatively correlates with liver fibrosis 
as detected by histology and FibroScan. World J Gastroenterol 
2015; 21(25): 7814-7823  Available from: URL: http://www.
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INTRODUCTION
Hepatic fibrosis develops as a wound-healing response 
of the liver to cellular injury, reflecting the balance 
between liver repair and scar formation[1]. Upon 
injury, the activated hepatic stellate cells (HSC) 
undergo transition into proliferative, profibrogenic, 
contractile myofibroblasts, which are responsible 
for the excess deposition of the extracellular matrix 
(ECM)[2,3]. The eventual structural abnormalities, which 
result from the histologic rearrangement of various 
types of collagens, proteoglycans, and structural 
glycoproteins and the excess deposition of ECM[2,4-7] 
cause increased liver stiffness (LS). When injury 
persists, fibrosis may advance into cirrhosis-the most 
severe stage, which may then further progress into 
hepatocellular carcinoma (HCC)[1,2,8]. Liver fibrosis is 
caused by diverse etiologies that include alcoholic and 
nonalcoholic steatohepatitis, chronic viral hepatitis, 
autoimmune disorders, and toxins[1,4,9].
Liver biopsy is the gold standard method for 
the identification of hepatic fibrosis. As this proce-
dure is invasive, painful, and carries the risk of com-
plications[10-12], other alternatives have been developed, 
such as noninvasive transient elastography (TE), 
serum-based aspartate aminotransferase-to-platelet 
ratio index, and Fibrotest[13,14]. TE is an ultrasound-
based examination method that measures the fibrosis-
related rigidity of the liver tissue, with the velocity of 
the share wave being directly related to LS, expressed 
as the LS value[15]. Using this method, the progress of 
fibrosis and early asymptotic cirrhosis can be assessed 
with high sensitivity and specificity. However, not all 
information needed for the diagnosis of fibrosis can be 
obtained from TE examination, such as the histologic 
liver conditions, including necroinflammation. 
MicroRNAs (miRNA) are short regulating RNA 
molecules that interfere with gene expression at 
the posttranscriptional level by way of inducing 
translational arrest, which in turn leads to reduced 
or prevented protein synthesis[3]. As a result of this 
negative modulating function, miRNAs fine-tune 
the expression of genes involved predominantly in 
normal cellular processes, such as development, 
differentiation, and proliferation[16]. Deregulated miRNA 
expression in comparison to normal state has been 
found in many disorders, including liver diseases[17,18]. 
In hepatic fibrosis, the members of the miR-27, 
miR-29, and miR-19 families have been reported to 
show altered expression[5,7,8,19]. These miRNAs either 
hinder the expression of various ECM components 
(miR-29) or regulate the signal transduction pathways 
connected to fibrosis (miR-29)[6,8,20] or the resting state 
of HSCs (miR-27)[21].
It has been suggested that an imbalance in the 
normal miRNA pattern can be measured long before 
the onset of a disease[22]. Therefore, in the present 
Table 1  Clinicopathologic data of patients with liver fibrosis of various etiologies
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study, the relative expression levels of selected miRNAs 
that are characteristically up- or downregulated in 
HCC in comparison to non-tumorous liver tissue[23] 
were determined in hepatic fibrosis samples of various 
etiologies. We wished to find out the degree to which 
these levels were altered in fibrosis and how they 
correlated with fibrosis stage (analyzed by histology 
and METAVIR scoring system) and LS values (measured 
by TE), as well as with serum alanine aminotransferase 
(ALT) levels.
MATERIALS AND METHODS
Patients characteristics
Biopsy samples of 52 patients were selected from the 
archives of the First Department of Internal Medicine 
at the University of Pécs, the Hepatology Center 
Buda in Budapest and the Second Department of 
Pathology at the Semmelweis University, Budapest. 
Selection was based on two criteria: diagnosis of 
histologically confirmed chronic, diffuse liver disease 
and LS measurement with intervals no longer than 3 
mo between the two examinations. Permission for the 
retrospective analysis of the samples was obtained 
from the local Ethical Committee (45727-2/2013/EKU) 
based on the ethical guidelines of the 1975 Declaration 
of Helsinki. Patients were aged between 15 and 67 
years with an average of 45.18 years. The female/
male ratio was 35/17. ALT serum values were also 
recorded at the time of liver biopsy.
The cases were selected to represent the diverse 
etiology of fibrosis: 24 cases of chronic viral hepatitis, 
including 22 hepatitis C virus (HCV) and 2 hepatitis 
B virus (HBV) infections; 19 autoimmune cases, 
including 8 autoimmune hepatitis (AIH), 6 primary 
biliary cirrhosis (PBC), 2 primary sclerosing cholangitis 
(PSC), and 3 overlapping syndrome cases (AIH/PBC 
and AIH/PSC); 9 cases of mixed etiology, including 1 
case of alcoholic and 2 of nonalcoholic liver diseases 
(ALD and NAFLD, respectively) and 6 cryptogenic 
cases (Table 1). Accordingly, three sample groups were 
formed for analysis: autoimmune (AIH, PBC, PSC, 
and overlaps), chronic viral hepatitis (HCV, HBV), and 
mixed etiology (ALD, NAFLD, cryptogenic).
Histology
Biopsy samples were processed according to routine 
pathology procedures. In brief, the small, 1-3-cm long 
samples were submerged in 10% neutral buffered 
formalin (in PBS, pH 7.0) and fixed for 24 h at room 
temperature. Following dehydration in a series of 
ethanols and xylene, the formalin-fixed samples were 
embedded in paraffin (FFPE samples). These samples 
were cut into 3-4-μm thick sections and stained with 
hematoxylin-eosin and picrosyrius red to highlight the 
connective tissue.
Determination of fibrosis
Histologic staging and TE examination were applied to 
determine the severity of fibrosis. Histologic staging 
was performed by two pathologists using the METAVIR 
scoring system from stages F0 to F4, with stage 
F0 indicating no fibrosis and stage F4 representing 
cirrhosis[24]. The noninvasive TE was carried out using 
FibroScan 502 (Echosens, Paris, France), with low LS 
values reflecting no or mild fibrosis and high LS values 
Etiology No. of cases Etiology subgroups
(n)
Fibrosis stage2
(n)
LS level (kPa) ALT level (U/L) HAI
Autoimmune 19  AIH (8)1  F0 (1)1 6.1 452 5
PBC (6) F1 (3) 5.3-7.6 20-904 0-4
PSC (2) F2 (4) 5.1-8.8 20-368 0-6
AIH/PBC (2) F3 (9) 5.5-17.1 17-558 0-12
AIH/PSC (1) F4 (2) 20.6 - 45.7 26-83 0-4
Chronic viral 24 HCV (22) F0 (3) 4.6-5.3 14-125 3-6
HBV (2) F1 (4) 3.8-6.8 12-35 2-6
F2 (4) 5.4-7.6 20-88 3-4
F3 (11) 5.6-20.4 12-257 0-8
F4 (2) 18.0-26.3 60-108 0-10
Mixed etiology   9 ALD (1) F0 (1) 4.9 71 0
NAFLD (2) F1 (2) 3.7-4.1 252-272 0
Cryptogenic (6) F2 (3) 5.3-11.9 13-101 0
F3 (1) 45 12 0
F4 (2) 75 23-32 0
Total 52 - F0 (5) 4.6-6.1 14-452 0-6
F1 (9) 3.7-7.6 12-904 0-6
  F2 (11) 5.1-11.9 13-368 0-6
  F3 (21) 5.5-45.0 12-558 0-12
F4 (6) 18.0-75.0 23-108 0-10
1Number of patients included in the subgroup; 2METAVIR. LS: Liver stiffness; ALT: Alanine aminotransferase; HAI: Histologic activity index; AIH: 
Autoimmune hepatitis; PBC: Primary biliary cirrhosis; PSC: Primary sclerosing cholangitis; HCV: Hepatitis C virus; HBV: Hepatitis B virus; ALD: Alcoholic 
liver disease; NAFLD: Nonalcoholic fatty liver disease.
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implying advanced fibrosis or cirrhosis. The elapsed 
time between date of histologic sampling and date of 
LS measurement was a maximum of 3 mo, with an 
average of 1.5 mo.
RNA isolation
RNA was isolated from several 3-4-μm thick sections 
using the RNeasy FFPE Kit (Qiagen, Venlo, Netherlands) 
according to the manufacturer’s instructions with 
modifications for copurification of miRNAs[25]. Traces 
of genomic DNA were eliminated using Turbo DNase 
digestion (Ambion, Austin, TX, United States).
Reverse transcription and quantitative PCR
Expression of individual miRNAs was determined 
using the following TaqMan MicroRNA Assays (Life 
Technologies of Thermo Fisher Scientific Inc., Waltham, 
MA, United States): miR-21 (ID: 000397), miR-122 
(ID: 002245), miR-140 (ID: 000462), miR-214 
(ID: 002306), miR-221 (ID: 000524), miR-222 
(ID: 002276), and miR-224 (ID: 002099). Reverse 
transcription (RT) and quantitative (q)PCR were 
performed according to the manufacturer’s instructions. 
Briefly, RT reaction was carried out using the TaqMan 
MicroRNA Reverse Transcription Kit in a final volume 
of 7.5 μL containing 10 ng total RNA. The qPCR was 
performed using TaqMan Universal PCR Master Mix No 
AmpErase UNG in a final volume of 10 μL containing 
0.65 μL RT product. The amplification reaction was run 
in triplicate on an ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems of Thermo Fisher Scientific 
Inc.). Relative expression was calculated by the 2-
∆∆Cq formula, applying miR-140 as the most stable 
reference determined by the NormFinder application[26] 
and normalized to the median ∆Cq value of F0 liver 
samples.
Statistical analysis
The differences between fibrosis stages F0-F4 were 
analyzed with a nonparametric Kruskal-Wallis analysis 
of variance and median test using STATISTICA software, 
version 9.1 (StatSoft Inc., Tulsa, OK, United States). 
Correlation analyses between miRNA expression and 
fibrosis stage, LS values, and ALT levels were performed 
with a nonparametric Spearman rank order correlation 
using GraphPad PRISM software, version 5.01 (GraphPad 
Software Inc, La Jolla, CA, United States). A P value of 
0.05 was set as the threshold for statistical significance. 
The statistical methods of this study were reviewed 
by Istvan Kenessey from the Second Department of 
Pathology, Semmelweis University.
RESULTS
Determination of fibrosis
The METAVIR scoring system allowed an unambiguous 
determination of fibrosis stages in each tissue sample. 
In contrast, the noninvasive LS measurement showed 
a wide range of values and when matched with the 
corresponding METAVIR stages, an overlap between 
the neighboring ranges was observable (Table 1). This 
was predominantly manifested in cases of LS value 
ranges that corresponded to fibrosis stages F0-F3. In 
addition, the LS value ranges showed slight variances 
between the various etiology groups. Yet, a highly 
significant correlation was found between the gradually 
increasing LS values and fibrosis stage (r = 0.8; P < 
0.01), as presented in Figure 1.
Expression of individual miRNAs in relation to METAVIR 
stage
Expression of individual miRNAs showed deregulated 
patterns in stages F1-F4 in comparison to stage F0, but 
the observed differences, except for one case, did not 
reach the set threshold for statistical significance. The 
exception was miR-122, in which case the expression 
in stage F4 was decreased as compared with stage 
F0 (P < 0.04) (Figure 2). The expression differences 
were close to reaching a statistical significance in two 
cases: miR-122 between stages F1 and F4 (P = 0.06) 
and miR-214 between stages F2 and F4 (P = 0.07). 
When looking at the expressional patterns of individual 
miRNAs, in general, the levels were lower in stages 
F1-F4 in comparison to F0, showing an increasing 
tendency in case of miR-214 from F2 to F4, miR-222 
from F1 to F4 and miR-224 from F2 to F4 (Figure 2). 
Nevertheless, the differences in the three etiologic 
groups did not reach the set threshold for statistical 
significance. 
Correlation of miRNA expression with fibrosis and ALT 
values
In relation to miRNA expression and fibrosis, miR-122 
and miR-221 showed a negative correlation with 
METAVIR stage (P < 0.01 and P < 0.03, respectively) 
(Figure 3A), and miR-122 was found to correlate 
negatively (P < 0.01) and miR-224 positively (P < 0.04) 
with LS values (Figure 3B). Furthermore, a positive 
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Figure 1  Correlation between fibrosis stage and liver stiffness measured 
by transient elastography. r = 0.8; P < 0.01.
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correlation of miR-21 was found between miRNA 
expression and ALT levels (P < 0.04) (Figure 3C). A 
summary of the correlation analyses is provided in 
Table 2. With respect to etiology, miR-122 expression 
correlated negatively with fibrosis stage and LS values 
(P < 0.02 and P < 0.05, respectively) in the mixed 
etiology group, and miR-221 level showed a negative 
correlation with fibrosis stage (P < 0.01) in the chronic 
viral hepatitis group, whereas a positive correlation 
between miR-21 and ALT values (P < 0.03) was found 
in the autoimmune group.
DISCUSSION
The diagnosis of liver fibrosis and the decision on 
therapy are important factors in the treatment of 
chronic liver diseases, with liver biopsy being the 
widely used procedure for the accurate determination 
of fibrosis. Owing to certain limitations of liver 
biopsy, such as possibility of serious complications, 
contradictions, sampling as well as intra- and inter-
observer errors[12], noninvasive approaches, such 
as TE, are available as alternatives. However, the 
diagnostic accuracy of TE is not entirely precise over 
the measuring range. Although the measured values 
increase with fibrosis stage, the method gives excellent 
results predominantly from advanced fibrosis (F2) to 
early and symptom-free cirrhosis (F4), and performs 
with limitations when early stage fibrosis (F0-F1) is 
to be determined, and when having to differentiate 
between F2/F3 stadium or in case of obese patients[27]. 
Yet, a highly positive correlation between fibrosis stage 
and LS values was found in the present study, which is 
supportive of the positive finding reported earlier[28]. 
There is a general need to find indicators at the 
molecular level to help predict disease progression. 
For example, hepatic cirrhosis is characterized by 
an increased proliferation rate that correlates with a 
higher tendency to develop HCC[29]. The miRNAs are 
foreseen to be such indicators based on their altered 
expression found in liver diseases, fibrosis[7,17], and liver 
carcinogenesis[23,30]. In addition, deregulated expression 
of miRNAs may be present long before the onset of 
a disease[22]. As alterations of miRNA expression in 
relation to fibrosis stage have predominantly been 
studied in chronic HCV-infected samples, we aimed, 
in the present study, to investigate the expression of 
fibrosis- and hepatocarcinogenesis-related miRNAs in 
hepatic fibrosis samples of various etiologies, and to 
correlate the found expression levels with the severity 
of fibrosis and serum ALT levels. 
Our results reveal a reduced level of miR-122 in 
stage F4 fibrosis as compared with stage F0, and 
miR-122 showed a negative correlation with fibrosis 
stage in fibrotic liver samples and, intriguingly, also with 
LS values. These findings are supported by reports of 
a negative correlation between miR-122 and fibrosis 
stage in chronic HCV infection, HCV-based HCC, and 
cirrhosis[31,32], and also by observations of a decreased 
level of miR-122 in NAFLD[33,34] and in HCC studies[23]. 
miR-122 is a liver-characteristic miRNA that composes 
about 70% of the total miRNAs found in normal 
hepatocytes[35], most probably due to the fact that it 
positively regulates the accumulation of cholesterol and 
triglycerides and the metabolism of fatty acids[16]. Thus, 
a decreased level of miR-122 in fibrotic liver biopsies 
may be interpreted as the result of compromised normal 
hepatocytic activity or as the eliminated suppressive 
function of miR-122 that hinders fibrogenesis. Namely, 
miR-122 has been found to suppress the proliferation of 
HSCs, resulting in decreased maturation of collagen by 
downregulating the expression of P4HA1, a key enzyme 
in collagen maturation[36]. miR-122 may also impede 
carcinogenesis[37], as expression of proteins involved 
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Figure 2  Relative miRNA expression in relation to fibrosis stage, detected in the biopsy samples of various etiologic backgrounds. The level of miR-122 is 
reduced in stage F4 as compared with stage F0 (P < 0.04), analyzed using a nonparametric Kruskal-Wallis analysis of variance and median test. The upper dotted 
line indicates twofold elevation in expression; the lower dotted line signifies a one-half reduction of expression.
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in the cell cycle, differentiation, and proliferation is 
downregulated by miR-122[38], and loss of miR-122 
in HCC is a frequent finding, which correlates with 
migration, invasion and in vivo tumorigenesis[39]. In 
association with HCV, miR-122 has been found to 
protect viral RNA from exonuclease degradation by 
binding at two positions near the 5′ end of the RNA 
molecule. However, the capacity of this protection 
seems to be independent of the promotion of HCV 
infectivity, indicating that miR-122 has other unknown 
functions in the viral life cycle[40]. Taken together, 
downregulation of miR-122 seems to be both a sensitive 
sign of hepatic injury and a possible step on the path 
toward liver cancer. 
2
0
-2
-4
-6
-8
lo
g2
 r
el
at
iv
e 
ex
pr
es
si
on
0                  1                   2                  3                  4
Fibrosis stage
miR-122
10
5
0
-5
-10
lo
g2
 r
el
at
iv
e 
ex
pr
es
si
on
0                   1                   2                   3                   4
Fibrosis stage
miR-221
2
0
-2
-4
-6
-8
lo
g2
 r
el
at
iv
e 
ex
pr
es
si
on
0                                      10                                    100
Liver stiffness (kPa)
miR-122
2
0
-2
-4
-6
lo
g2
 r
el
at
iv
e 
ex
pr
es
si
on
0                                       10                                      100
Liver stiffness (kPa)
miR-224
4
2
0
-2
-4
-6
-8
lo
g2
 r
el
at
iv
e 
ex
pr
es
si
on
0                                     100                                  1000
ALT (U/L)
miR-21
A
B
C
Figure 3  Correlation of miRNA expression with fibrosis stage, liver stiffness (measured by transient elastography), and alanine aminotransferase levels. A: 
The negative correlation of miR-122 (r = -0.4; P < 0.01) and miR-221 (r = -0.3; P < 0.03) with fibrosis stage; B: The negative correlation of miR-122 (r = -0.4; P < 0.01) 
and positive correlation of miR-224 (r = 0.3; P < 0.04) with liver stiffness; C: The positive correlation of miR-21 (r = 0.3; P < 0.04) with serum alanine aminotransferase 
(ALT) levels. The upper dotted lines indicate twofold elevation in expression; the lower dotted lines signify a one-half reduction of expression.
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Increased levels of miR-221, miR-224, and miR-21 
have been reported in HCC as these oncomiRs inhibit 
expression of tumor suppressor genes[23]. For example, 
downregulation of P27 and P57, as targets of miR-221 
and key regulators of cell cycle progression, has 
been found to promote cancer cell proliferation[30,41]. 
Moreover, miR-221 is observed to be increased in 
early preneoplastic stage, such as cirrhosis and 
steatosis or steatohepatitis[42-44], and is also found to be 
overexpressed in a mouse liver-regeneration model, 
in which the proliferation of hepatocytes is accele-
rated by miR-221 in vitro and in vivo in the presence 
of epidermal or hepatocytes growth factors (EGF or 
HGF), thereby facilitating a rapid S-phase entry of 
hepatocytes[45]. In HCV and nonalcoholic steatohepatitis 
biopsies, miR-221 is observed to increase with fibrosis 
stage and to correlate positively with expression 
levels of α1 chain of collagen type Ⅰ[46]. In contrast, 
statistical difference in miR-221 expression was not 
found in the present study; moreover, fibrosis stage 
showed a negative correlation with miR-221 expression 
in our samples and the samples of the chronic viral 
hepatitis group. An explanation for this could be that 
the representations of the F0-F4 cases, as well as the 
statistical methods used, were different; furthermore, 
the extent of regeneration was possibly different in 
the analyzed samples. Another reason could be the 
DNA methylation status of the miR-221 locus, as 
hypomethylation of this locus was found in HCC that 
contributed to the overexpression of miR-221[47]. 
miR-224 has been described to promote prolife-
ration, migration, and invasion in HCC by the activation 
of AKT signaling; thus, miR-224 has been suggested to 
play a role in liver carcinogenesis and progression[48]. 
With respect to fibrosis stage, the present study did 
not reveal any differences or correlations. However, LS 
values positively correlated with miR-224 expression, 
suggesting that a gradual increase in miR-224 level may 
occur in liver tissues prior to malignant transformation. 
Indeed, miR-224 expression has been found to correlate 
with fibrosis stage in chronic hepatitis C[49], and elevated 
levels of miR-224 have also been observed in chronic 
hepatitis C samples with steatosis and HCV-negative 
steatotic liver biopsies[50].
It has been reported that miR-21 reduces the 
expression of fibrogenesis-related tumor suppressor 
genes, such as SMAD-7, the negative regulator 
of transforming growth factor-β signaling[8,31], and 
proliferation-related PTEN, an inhibitor of the AKT 
pathway[51]. Positive correlation between miR-21 and 
fibrosis stage is reported in chronic HCV-infected 
patients and in a CCl4 mouse fibrosis model[31], and 
stimulation of the fibrogenic effect by miR-21 is also 
found in a HSC cell line[51]. In contrast, we did not find 
any difference or correlation between miR-21 and 
fibrosis stage or LS values in the present study, but 
positive correlation of miR-21 with serum ALT values 
was clearly visible. In our chronic viral hepatitis group, 
this correlation did not reach the set significance level, 
which is in partial agreement with data reported in 
chronic hepatitis C patients[31]. In addition, ALT levels 
have been found to correlate with serum miR-21 levels 
of chronic HCV patients, suggesting that miR-21 is an 
indicator of the extent of necroinflammation in the 
liver[52].
In the present study, the expression of several 
hepatocarcinogenesis-related miRNAs was assayed 
in fibrotic liver biopsy samples of various etiologies 
and correlated with fibrosis stage (measured by 
METAVIR) and, to the best of our knowledge, for the 
first time, with LS values (measured by TE). Reduced 
miR-122 expression was found in advanced fibrosis 
as compared with stage F0 and a negative correlation 
was observed not only with fibrosis stage, but with 
LS values as well. In addition, we detected a positive 
correlation between miR-224 and LS values, indicating 
the role of this oncomiR in advanced fibrosis, indicating 
a link between fibrosis and HCC. Nevertheless, an ideal 
staging tool should be able to discriminate not only 
between mild and advanced stages of fibrosis, but also 
between intermediate stages of fibrosis. Although this 
is a reasonable demand, the biologic variances may 
result in overlaps between the observed intermediate 
values, especially if the intermediate ranges are small. 
The main focus of the present study was to analyze 
fibrotic samples of different etiologic backgrounds. The 
limitation of our analysis is the small sample size in 
the various etiologic groups. Therefore, further studies 
are warranted in order to reveal whether the observed 
miRNA correlations are also characteristic of the 
various etiology groups or whether these relationships 
are only summed characteristics of the fibrosis samples 
by reason of the various etiologies. In conclusion, the 
observed negative correlation between fibrosis stage 
and LS values in case of miR-122 indicates that this 
molecule could be useful in assessing the severity of 
fibrosis regardless of etiology.
Table 2  Correlation of miRNA levels with fibrosis stage, liver 
stiffness, and alanine aminotransferase values
miRNA All samples 
(n  = 52)
Etiology groups
Autoimmune Viral Mixed
(n  = 19) (n  = 24) (n  = 9)
Fibrosis stage
   miR-122 r = -0.4 r = -0.3 r = -0.3 r = -0.8 
P < 0.01 P < 0.20 P < 0.10 P < 0.02
   miR-221 r = -0.3 r = -0.3 r = -0.5 r = -0.2 
P < 0.03 P < 0.20 P < 0.01 P < 0.40
Liver stiffness
   miR-122 r = -0.4, r = -0.4 r = -0.2 r = -0.7 
P < 0.01 P < 0.09 P < 0.30 P < 0.05
   miR-224 r = 0.3 r = 0.3 r = 0.1 r = 0.6
P < 0.04 P < 0.20 P < 0.70 P < 0.07
Alanine 
aminotransferase
   miR-21 r = 0.3 r = 0.5 r = 0.4 r = -0.4 
P < 0.04 P < 0.03 P < 0.09 P < 0.30
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Background
Hepatic fibrosis is a wound-healing response of the liver to cellular injury 
that is characterized by deposition of collagen fibers and contributes to the 
deterioration of normal liver function. When injury persists, fibrosis may advance 
into cirrhosis (the most severe stage of fibrosis) and further into hepatocellular 
carcinoma. Assessment of the stage of fibrosis is important for diagnosis 
and is predominantly based on liver biopsy. Owing to some limitations, other 
alternatives have been developed such as transient elastography.
Research frontiers
The regulatory role of microRNAs (miRNA) is to fine-tune the expression 
of genes involved in normal cellular processes, such as development, 
differentiation, and proliferation. For this reason, it may not be surprising 
that altered miRNA expression can be found in cancers and in several other 
pathologies, including liver diseases. Moreover, it has been suggested that an 
imbalance in the normal miRNA pattern is measurable long before the onset of 
a disease, indicating that miRNAs may be useful molecules in diagnostics.
Innovations and breakthroughs
There is a need to find indicators that will help predict the progression of 
a disease. As miRNAs have been reported to show altered expression in 
fibrosis and have also been suggested to play role in liver carcinogenesis, 
these molecules may be useful candidates. miRNA expression in relation to 
fibrosis stage has predominantly been investigated in chronic hepatitis C virus-
infected samples. Therefore, in the current study, the authors investigated 
miRNA expression in samples of diverse etiologies, including autoimmune and 
chronic viral hepatitis and alcoholic and nonalcoholic liver diseases to find out 
whether miRNA levels become altered in fibrosis and whether they could be 
correlated with fibrosis stage and liver stiffness values measured by transient 
elastography.
Applications
The reduced expression of miR-122 observed in stage F4 as compared 
with stage F0 and the negative correlation of miR-122 levels with fibrosis 
stage and liver stiffness suggest that miR-122 could be a useful molecule to 
assess fibrosis regardless of etiology. However, further studies are warranted 
with larger sample sizes. Furthermore, the staging tool should also be able 
to discriminate between intermediate stages of fibrosis, although biologic 
variances themselves may result in overlaps between the intermediate values.
Terminology
miRNAs are regulating molecules that interfere with gene expression upon 
binding to the untranslated regions of mRNAs and induce translational arrest, 
the result being reduced or prevented protein synthesis. Transient elastography 
is an ultrasound-based examination method for the noninvasive assessment 
of liver stiffness in fibrosis, with the value increasing with the advancement of 
fibrosis.
Peer-review
The novelty of the study is the correlation analysis of transient elastography and 
miRNA expression in samples obtained from chronic liver disease of various 
etiologies. Although the study examined a limited sample size in each subgroup 
of fibrosis-related liver diseases, the presented results are in agreement 
with recent reports that support a strong correlation between decrease of 
miR-122 levels and severity of fibrosis or increase in liver stiffness. The most 
significant finding of the study is that miR-122 levels are altered independent 
of the etiologic cause of liver damage. The presented evidences support the 
usefulness of miR-122 as an indicator of fibrosis progression.
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